Press Releases

New Tubulis Paper in Blood highlights potential of next-generation ADC for effective & safe treatment of acute myeloid leukemia

Together with our collaborators at LMU Klinikum Munich, the German Cancer Consortium DKTK and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) we have published a new paper in Blood, highlighting the great potential of a next-generation ADC for the effective & safe treatment of acute myeloid leukemia (AML) in preclinical in vivo models.

With a 5-year overall survival rate of 29.5% in America, AML treatment remains a challenge and the demand for new therapeutic options is high. Therefore, we utilized our novel P5 conjugation platform to create 20D9-ADC targeting a commonly occurring FTL3 mutation in AML. We could not only show a significant and durable tumor reduction but also reduced liver toxicity in preclinical cancer models. Moreover, a combined treatment with the marketed therapeutic midostaurin, a tyrosine kinase inhibitor, showed a synergistic effect broadening possible application scenarios for 20D9-ADC.

Read the full Blood article here.

Contacts

For Tubulis
Dominik Schumacher,
CEO & Co-Founder
Phone: +49 175 800 5594
Email: contact@tubulis.com

Media Requests for Tubulis
Trophic Communications
Stephanie May or Marie Weickert
Phone: + 49 171 185 5682
Email: tubulis@trophic.eu

Share Article

More Press Releases

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024